[1]杨亚琴,杨 文,刘淑婷,等.微小RNA-155和血清β2微球蛋白检测在血液透析患者并发心血管疾病中的诊断价值[J].陕西医学杂志,2024,(1):113-117.[doi:DOI:10.3969/j.issn.1000-7377.2024.01.025]
　YANG Yaqin,YANG Wen,LIU Shuting,et al.Diagnostic value of microRNA-155 and serum β2-microglobulin in hemodialysis patients with cardiovascular disease[J].,2024,(1):113-117.[doi:DOI:10.3969/j.issn.1000-7377.2024.01.025]
点击复制

微小RNA-155和血清β2微球蛋白检测在血液透析患者并发心血管疾病中的诊断价值
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年1期
页码:
113-117
栏目:
临床检验
出版日期:
2024-01-31

文章信息/Info

Title:
Diagnostic value of microRNA-155 and serum β2-microglobulin in hemodialysis patients with cardiovascular disease
作者:
杨亚琴1; 杨 文2; 刘淑婷2; 孙亦兵2
(1.河北北方学院附属第一医院急诊科,河北 张家口 075000; 2.河北北方学院附属第一医院血液净化科,河北 张家口 075000)
Author(s):
YANG Yaqin; YANG Wen; LIU Shuting; SUN Yibin
(Department of Emergency,the First Affiliated Hospital of Hebei North University,Zhangjiakou 075000,China)
关键词:
微小RNA-155;  血清β2微球蛋白;  心血管疾病;  血液透析;  可溶性生长刺激表达基因2蛋白;  肌钙蛋白T;  氨基末端脑利钠肽前体
Keywords:
miRNA-155;  Serumβ2-microglobulin;  Cardiovascular disease;  Haemodialysis;  sST2;  TNT;  NT-proBNP
分类号:
R 459.5
DOI:
DOI:10.3969/j.issn.1000-7377.2024.01.025
文献标志码:
A
摘要:
目的:探究血液透析患者中微小RNA-155(miRNA-155)和血清β2微球蛋白的表达与心血管疾病风险的相关性。方法:选择100例血液透析患者中患有心血管疾病的患者为试验组,100例血液透析患者中无心血管疾病的患者为对照组。采取血液透析患者一定量的静脉血样,检测患者血清中可溶性生长刺激表达基因2蛋白(sST2)、肌钙蛋白T(TNT)与血清氨基末端脑利钠肽前体(NT-proBNP)。对所有研究对象的心血管疾病进行评估。采用实时荧光定量PCR(qPCR)检测血清中的miRNA-155的水平,采用速率散射比浊法检测血清β2微球蛋白水平。结果:试验组的年龄、糖尿病史的比例、开始透析的平均年龄、TNT平均水平、NT-proBNP平均水平与sST2平均水平高于对照组(均P<0.05)。同时,对照组的平均透析时间要高于试验组(P<0.05)。试验组血清中的miRNA-155含量明显低于对照组血清中的miRNA-155的含量(P<0.05),同时血清miRNA-155表达水平与TNT、NT-proBNP、sST2的水平呈现负相关性(均P<0.05)。试验组血清中的β2微球蛋白含量明显高于对照组血清中的β2微球蛋白的含量(P<0.05),同时血清β2微球蛋白水平与TNT、NT-proBNP、sST2的水平呈现正相关性(均P<0.05)。ROC曲线分析显示血清miRNA-155与β2微球蛋白诊断的曲线下面积(AUC)分别为0.912(95%CI:0.798～0.985)与0.842(95%CI:0.793～0.972)。结论:sST2、TNT NT-proBNP可以有效地对血液透析患者的心血管疾病作出诊断,同时患有心血管疾病的血液透析患者血清中miRNA-155表达水平较低,血清β2微球蛋白的表达水平较高; 因此miRNA-155与血清β2微球蛋白在预测血液透析患者并发心血管疾病时具有较高价值。
Abstract:
Objective:To investigate the correlation between the expression of microRNA-155(miRNA-155),serum β2-microglobulin and the risk of cardiovascular disease in hemodialysis patients.Methods:A totalo of 100 hemodialysis patients which have cardiovascular diseases were chose as the experimental group.At the same time,100 hemodialysis patients without cardiovascular were selected as the control group.There were blood samples collection from the 200 selected hemodialysis patients,and the serum soluble growth stimulating gene 2 protein(sST2),troponin T(TNT)and serum N-terminal pro-brain natriuretic peptide(NT-proBNP)were detected.All subjects were assessed for cardiovascular disease.The level of miRNA-155 in serum was examined by qPCR.The serum β2-microglobulin level was detected by rate scattering turbidimetry.Results:The age,the proportion of diabetes history,the average age of starting dialysis,the average level of TNT,the mean level of NT-proBNP and sST2 in the experimental group were higher than those in the control group(all P<0.05).At the same time,the average dialysis time in the control group was longer than the average dialysis time in the experimental group(P<0.05).The content of miRNA-155 in serum of experimental group was significantly lower than that of control group(P<0.05).Meanwhile,the expression level of serum miRNA-155 was negatively correlated with the levels of TNT,NT-proBNP and sST2(all P<0.05).The content of β2-microglobulin in serum of experimental group was significantly higher than that of control group(P<0.05).At the same time,the level of serum β2-microglobulin was positively correlated with the levels of TNT,NT-proBNP and sST2(all P<0.05).ROC curve analysis showed that the AUC of serum miRNA-155 and β2-microglobulin were 0.912(95%CI:0.798 to 0.985)and 0.842(95%CI:0.793 to 0.972),respectively.Conclusion:The sST2,TNT and NT-proBNP can effectively diagnose cardiovascular diseases in hemodialysis patients,and the expression level of miRNA-155 in serum of hemodialysis patients with cardiovascular diseases is low,the expression level of serum β2-microglobulin is high.Therefore,miRNA-155 and serum β2-microglobulin have outstanding value in predicting cardiovascular diseases in hemodialysis patients.

参考文献/References:

[1] 袁子阳,张艳,张伟.基于铁稳态代谢探讨铁死亡在心血管疾病中的作用及中医药治疗进展[J].中国实验方剂学杂志,2023,7(27):1-14.
[2] 陈伟伟,高润霖,刘力生,等.中国心血管病报告2017[J]. 中国循环杂志,2018,33(1):1-8.
[3] SARNAK M J,LEVEY A S.Cardiovascular disease and chronic renal disease:A new paradigm[J].Am J Kidney Dis,2000,35(Suppl 1):117-131.
[4] JABLONSKI K L,CHONCHOL M.Recent advances in the management of hemodialysis patients:A focus on cardiovascular disease[J].F1000Prime Rep,2014:1172-1176.
[5] 杨军,万晨阳,李婷,等.血清可溶性生长刺激基因表达蛋白2、腱糖蛋白C水平与维持性血液透析患者并发心血管事件的关系[J].中国血液净化,2020,19(6):376-380.
[6] GRUSON D,LEPOUTRE T,AHN S A,et al.Increased soluble ST2 is a stronger predictor of long-term cardio-vascular death than natriuretic peptides in heart failure patients with reduced ejection fraction[J].Int J Cardiol,2014,172(1):250-252.
[7] 何蕾,彭剑,郑璇,等.血清可溶性致癌抑制因子2水平与急性ST段抬高型心肌梗死患者近期临床预后的相关性研究[J].中国循环杂志,2017,32(1):41-45.
[8] 漆星,文清,张瑶琳,等.心肌标志物联合检测对血液透析患者并发心血管疾病的诊断价值[J].国际检验医学杂志,2023,44(14):1704-1708.
[9] SARNAK M J,LEVEY A S,SCHOOLWERTH A C,et al.Kidney disease as a risk factor for development of cardiovascular disease:A statement from the american heart association councils on kidney in cardiovascular disease,high blood pressure research,clinical cardiology,and epidemiology and prevention[J].Circulation,2003,108(17):2154-2169.
[10] VANHOLDER R,BAURMEISTER U,BRUNET P,et al.A bench to bedside view of uremic toxins[J].J Am Soc Nephrol,2008,19(5):863-870.
[11] LIM Y J,SIDOR N A,TONIAL N C,et al.Uremic toxins in the progression of chronic kidney disease and cardiovascular disease:Mechanisms and therapeutic targets[J].Toxins(Basel),2021,13(2):142.
[12] 艾世宜,李佳娜,李星.miRNA-126和miRNA-92a在冠心病患者血清中的表达水平及临床意义[J].陕西医学杂志,2021,50(4):443-446.
[13] ZHANG L,CHEN X,SU T,et al.Circulating miR-499 are novel and sensitive biomarker of acute myocardial infarction[J].J Thorac Dis,2015,7(3):303-308.
[14] WANG C,ZHANG C,LIU L,et al.Macrophage-derived mir-155-containing exosomes suppress fibroblast proliferation and promote fibroblast inflammation during cardiac injury[J].Mol Ther,2017,25:192-204.
[15] COURTIES A,SELLAM J,MAHEU E,et al. Coronary heart disease is associated with a worse clinical outcome of hand osteoarthritis:A cross-sectional and longitudinal study[J].RMD Open,2017,3(1):1-8.
[16] HALUSHKA M K,MITCHELL R N,PADERA R F.Heart failure therapies:New strategies for old treatments and new treatments for old strategies[J].Cardiovasc Pathol,2016,25(6):503-511.
[17] ZHANG Z J,CHEN H Z,ZHOU L T,et al.Macrophage-derived exosomal miRNA-155 promotes tubular injury in ischemia-induced acute kidney injury[J].Int J Mol Med,2022,50(3):116.
[18] LONNEMANN G,KOCH K M.Beta(2)-microglobulin amyloidosis:Effects of ultrapure dialysate and type of dialyzer membrane[J].J Am Soc Nephrol,2002(S13):72-77.
[19] WINCHESTER J F,SALSBERG J A,LEVIN N W.Beta-2 microglobulin in ESRD:An in-depth review[J].Adv Ren Replace Ther,2003,10(4):279-309.
[20] 张楷元,焦汇楠.糖尿病肾损伤患者尿微量清蛋白、血清β2微球蛋白、血清胱抑素C检测的临床意义[J].临床医学,2023,43(3):56-57.
[21] 刘毅龙,陈鹏宇,雷江,等.SGLT-2抑制剂在2型糖尿病合并心血管疾病治疗中的应用研究进展[J].陕西医学杂志,2019,48(3):407-409.
[22] 陈秀娟,朱昭明,苏宝印.参芪清毒胶囊对血液透析患者营养指标、氧化应激、炎性因子、残余肾功能的影响[J].陕西中医,2021,42(3):334-337.
[23] 张玲,张太君,黎颖,等.五色培元固本膏对维持性血液透析患者细胞免疫功能的影响[J].陕西中医,2020,41(12):1751-1754.
[24] 张羽,廖畅,吕鑫,等.外周血单个核细胞NF-κB水平与维持性血液透析患者心血管疾病及预后的关系[J].现代医学,2019,47(8):951-955.
[25] RANGASWAMI J,MCCULLOUGH P A.Heart failure in end-stage kidney disease:Pathophysiology,diagnosis,and therapeutic strategies[J].Semin Nephrol,2018,38(6):600-617.
[26] 李勇,宋嶶.新型生物标志物在心血管疾病中的应用[J].国际检验医学杂志,2019,40(18):2276-2279.

备注/Memo

备注/Memo:
基金项目:河北省卫生健康委员会科研计划项目(20231423)
更新日期/Last Update: 2024-01-05